SCHEMBL1033746

SCHEMBL1033746

COc1cc(Nc2ncc(F)c(Nc3ccc(NS(=O)(=O)c4cccs4)cc3)n2)cc(OC)c1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 6/20 0.55
EGFR P00533 4/20 0.54
ITK Q08881 4/20 0.54
AURKA O14965 4/20 0.48
BTK Q06187 3/20 0.48
KDM4E B2RXH2 2/20 0.48
POLB P06746 1/20 0.48
FAM20C Q8IXL6 1/20 0.47
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47
HTT P42858 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
PTK2 Q05397 4/20 0.47
LRRK2 Q5S007 3/20 0.47
CDC7 O00311 2/20 0.46
PLK4 O00444 2/20 0.46
CHEK1 O14757 2/20 0.46
MAPK13 O15264 2/20 0.46
PDPK1 O15530 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1036580 0.93 EGFR (0.61) SYKEGFRITKAURKABTK
SCHEMBL1075026 0.90 PTK2 (0.53) SYKEGFRITKAURKABTK
SCHEMBL1035455 0.85 SYK (0.58) SYKEGFRITKAURKABTK
SCHEMBL1038905 0.85 SYK (0.54) SYKEGFRITKAURKABTK
SCHEMBL1221693 0.84 SYK (0.64) SYKEGFRITKAURKABTK
SCHEMBL12894667 0.83 SYK (0.62) SYKEGFRITKAURKABTK
SCHEMBL1037441 0.83 SYK (0.56) SYKEGFRITKAURKABTK
SCHEMBL1222410 0.81 SYK (0.58) SYKEGFRITKAURKABTK
SCHEMBL1222402 0.81 SYK (0.57) SYKEGFRITKAURKABTK
SCHEMBL1222117 0.81 SYK (0.57) SYKEGFRITKAURKABTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098288-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 US claimed
EP-2276747-A1 SULFONAMIDES AS ZAP-70 INHIBITORS Cellzome Limited (GB) 2011-01-26 EP claimed
WO-2009112490-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2009-09-17 WO claimed
US-20110098288-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 US disclosed
US-20110098288-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2011-04-28 US disclosed
EP-2276747-A1 SULFONAMIDES AS ZAP-70 INHIBITORS Cellzome Limited (GB) 2011-01-26 EP disclosed
WO-2009112490-A1 SULFONAMIDES AS ZAP-70 INHIBITORS CELLZOME LIMITED (GB) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098288-A1 SULFONAMIDES AS ZAP-70 INHIBITORS ZAP70, SYK, LCK SYK 2/4885EGFR 2061/4885ITK 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.